KRAS and neoplasm: Tumor response was also evaluated in the human colorectal cancer model HCT116, which harbors a G13D mutation in KRAS rendering the tumor less sensitive to cetuximab treatment (12), as it is equally important to demonstrate that imaging biomarkers are negative when a tumor is nonresponsive to therapy.